Insulin Resistance — A Canadian Clinical Guide
Insulin resistance is when the body's cells respond poorly to insulin, so the pancreas produces more of it to keep blood sugar in range. It affects an estimated one in three Canadians and is a leading precursor to type 2 diabetes, cardiovascular disease, fatty liver, and PCOS, yet most people stay symptom-free for years and only learn of it through routine bloodwork such as HbA1c, fasting glucose, and fasting insulin. The most evidence-backed response is lifestyle-first: a sustained 5 to 7 percent weight loss, at least 150 minutes of weekly activity, fewer refined carbohydrates, and better sleep. The landmark Diabetes Prevention Program cut progression to type 2 diabetes by 58 percent over three years through these changes alone.
What insulin resistance actually is
Insulin is a hormone produced by the beta cells of the pancreas. Its primary job is to act as a key: when blood glucose rises after a meal, insulin binds to receptors on cells throughout the body — primarily in muscle, liver, and adipose tissue — unlocking those cells so glucose can enter and be used for energy or stored for later.
Insulin resistance is what happens when those locks stop responding normally to the key.
When cells resist insulin's signal, the pancreas compensates by producing more insulin. For a while, this keeps blood glucose within the normal range — the pancreas just works harder. But the elevated insulin itself causes downstream problems: it promotes fat storage (particularly in the visceral compartment around the organs), drives sodium retention, contributes to inflammation, and stimulates ovarian androgen production in women with PCOS. Eventually, if the burden is not addressed, the pancreas can't keep up — blood glucose rises into the prediabetes range, and then into type 2 diabetes.
Diabetes Canada's Clinical Practice Guidelines and the 2020 Canadian Adult Obesity Clinical Practice Guideline both treat insulin resistance as a central metabolic target — addressable years before type 2 diabetes becomes established.
Take the free 3-minute quiz
How common is insulin resistance in Canada?
Prevalence estimates vary based on the measurement criteria used, but the numbers are large regardless of how you count. Diabetes Canada estimates that roughly 11.7 million Canadians — approximately one in three adults — are living with prediabetes or diabetes, the two most common insulin-resistance endpoints. Many more have measurable insulin resistance without yet crossing those diagnostic thresholds.
Risk is not uniform. The following factors meaningfully increase likelihood:
- Abdominal obesity. Waist circumference above 88 cm (35 inches) in women or 102 cm (40 inches) in men is one of the most reliable clinical indicators.
- Physical inactivity. Sedentary behaviour impairs insulin signalling independently of body weight.
- Sleep disruption. Even one week of sleep restriction (five hours per night) produces measurable insulin resistance in otherwise healthy adults, per studies published in Annals of Internal Medicine.
- Ethnicity. South Asian, East Asian, Middle Eastern, and Indigenous Canadians develop insulin resistance at lower body-weight thresholds than population averages suggest, a pattern the Canadian Diabetes Risk Questionnaire (CANRISK) explicitly accounts for.
- Family history. First-degree relative with type 2 diabetes substantially increases personal risk.
- PCOS. Estimated 65–95% of women with PCOS have measurable insulin resistance, per the Endocrine Society's PCOS clinical practice guideline.
How insulin resistance is diagnosed
There is no single gold-standard test for insulin resistance in routine clinical practice. Diabetes Canada's CPG and most Canadian clinical guidelines approach it through a combination of blood markers, physical measurements, and clinical history.
The most common tests ordered by Canadian family physicians:
- Fasting plasma glucose. Normal: below 5.6 mmol/L. Prediabetes range: 5.6–6.9 mmol/L.
- HbA1c (glycated hemoglobin). Reflects average blood glucose over the past two to three months. Normal: below 5.7%. Prediabetes range: 5.7–6.4%.
- Fasting insulin. Not universally ordered but helpful for assessing compensatory hyperinsulinemia before glucose rises. Normal range varies by lab, but fasting insulin above 85–90 pmol/L is typically flagged.
- HOMA-IR. A calculated index — (fasting glucose in mmol/L × fasting insulin in pmol/L) / 135 — where values above 2.0–2.5 suggest insulin resistance in most reference frameworks.
- Lipid panel. Elevated triglycerides (above 1.7 mmol/L) and low HDL cholesterol are common metabolic signatures of insulin resistance.
Physical measurements:
- Waist circumference is one of the most clinically useful single markers. The thresholds differ by ethnicity — a detail that is increasingly recognized in Canadian clinical practice.
The oral glucose tolerance test (OGTT) is more sensitive than fasting glucose alone and is used in specific clinical contexts (gestational diabetes screening, diagnosing early impaired glucose tolerance). It is not routine in most Canadian primary-care practices for initial insulin-resistance screening.
The symptom map
Most people with insulin resistance have no dramatic symptoms, which is why it is so frequently undetected until glucose has already risen into the prediabetes range. Symptoms that are present tend to be non-specific:
Metabolic and physical signals:
- Weight gain that resists effort, particularly in the abdominal area. Visceral fat accumulation is driven partly by high circulating insulin promoting fat storage in that compartment.
- Fatigue after meals, sometimes described as an energy crash 1–2 hours after eating — especially after carbohydrate-heavy meals.
- Persistent hunger despite eating adequate calories, driven by cells not receiving sufficient glucose even as blood levels are elevated.
- Brain fog and difficulty concentrating, particularly in the hours after high-carbohydrate meals.
Skin and hormonal signals:
- Acanthosis nigricans — dark, velvety patches of skin in folds at the neck, underarms, or groin. This is a classic visible marker of hyperinsulinemia and is specifically noted in Diabetes Canada's CPG as a clinical sign.
- Skin tags, which correlate with acanthosis nigricans and elevated insulin.
- Menstrual irregularity in women — insulin stimulates ovarian androgen production, which disrupts the hypothalamic-pituitary-ovarian axis.
Cardiovascular signals:
- Elevated blood pressure — insulin promotes sodium retention, which raises blood pressure.
- Elevated triglycerides and low HDL on bloodwork.
The most important thing to understand about the symptom map is that many of these signals are present for years before blood glucose moves into the prediabetes range. Treating insulin resistance as a pre-clinical condition worth addressing, rather than waiting for the diagnosis, is the entire logic of early metabolic intervention.
What drives insulin resistance
Understanding the drivers is important because the evidence-based interventions are direct responses to them:
Driver 1 — Visceral adiposity. Fat stored in and around the organs — the liver, pancreas, and deep abdominal compartment — releases free fatty acids and inflammatory cytokines that directly interfere with insulin receptor signalling. This is the mechanism behind the well-established link between abdominal obesity and insulin resistance.
Driver 2 — Physical inactivity. Muscle is the primary disposal site for dietary glucose in a healthy metabolic state. Inactive muscle loses insulin sensitivity rapidly. The mechanism is partly GLUT4 transporter density — sedentary muscle has fewer of the transporters that move glucose into cells during and after exercise.
Driver 3 — Sleep disruption. The cortisol and growth-hormone rhythms that govern insulin sensitivity are tightly coupled to sleep architecture. Research published in Annals of Internal Medicine has shown that restricting sleep to five hours for even one week produces measurable insulin resistance in healthy adults. This is not a marginal effect.
Driver 4 — Chronic stress. Cortisol is a counter-regulatory hormone — it raises blood glucose. Chronic cortisol elevation from psychological or physiological stress creates persistent mild hyperglycemia, which drives compensatory insulin production over time.
Driver 5 — Ultra-processed dietary patterns. High refined-carbohydrate intake drives large, repeated postprandial insulin spikes. Over time, constant demand on the beta cells and persistent hyperinsulinemia appear to degrade receptor sensitivity through mechanisms including receptor downregulation.
What the evidence shows actually helps
Diet
The research base is consistent: the dietary pattern most reliably associated with improved insulin sensitivity reduces the refined-carbohydrate load and the corresponding postprandial insulin spikes.
No single named diet owns the evidence. Mediterranean-pattern eating, lower-carbohydrate approaches, and DASH-style diets all show meaningful benefit in randomized controlled trials. What they share:
- Fewer refined carbohydrates and added sugars — white bread, white rice, sweetened beverages, and ultra-processed snacks drive the largest postprandial insulin responses.
- Adequate dietary fibre — soluble fibre (from oats, legumes, vegetables) slows glucose absorption and reduces the insulin spike per gram of carbohydrate.
- Adequate dietary protein — roughly 1.2–1.6 g per kg of body weight per day, spread across meals, improves satiety and reduces overall calorie intake without the metabolic penalty of high-carbohydrate eating.
- Healthy fats — monounsaturated and omega-3 fats do not spike insulin; some evidence suggests they support insulin receptor function.
A 2017 systematic review in Nutrients examined 17 RCTs and found that low-glycemic-index diets significantly reduced fasting insulin, fasting glucose, and HbA1c compared with higher-glycemic diets in adults with insulin resistance or prediabetes. The effect was consistent across Mediterranean and lower-carbohydrate versions.
A 2019 meta-analysis in Diabetes Care found that low-carbohydrate dietary patterns (less than 26% of calories from carbohydrates) produced greater short-term reductions in HbA1c than higher-carbohydrate approaches in adults with type 2 diabetes — and that the effect persisted at 12-month follow-up even as the dietary differences between groups narrowed somewhat.
Exercise
Exercise is one of the most potent reversers of insulin resistance, and part of its mechanism is independent of weight loss.
A single bout of moderate-to-vigorous exercise activates GLUT4 transporters in muscle through a signalling pathway that does not require insulin. This creates an acute insulin-sensitizing window of 24–72 hours following each session. The implication is practical: three to five exercise sessions per week provide near-continuous metabolic benefit, with or without weight change.
Resistance training deserves specific attention for insulin-resistant patients. Muscle mass is metabolically active tissue — the more you have, the more glucose can be disposed of per unit of insulin. The Canadian Society for Exercise Physiology 24-Hour Movement Guidelines recommend at least two muscle-strengthening sessions per week; for insulin resistance specifically, there is a strong case for prioritizing this type of training.
Walking, often underestimated, has a meaningful and consistent literature. Post-meal walks of even 10–15 minutes reduce postprandial glucose more than a single longer walk later in the day, per a 2022 meta-analysis in Sports Medicine. Walking after dinner is a practical, barrier-free intervention that most Canadians can add immediately.
The Diabetes Prevention Program (NEJM, 2002) found that 150 minutes per week of moderate physical activity combined with a 5–7% weight loss reduced incident type 2 diabetes by 58% in adults with prediabetes over three years — an effect significantly larger than the trial's medication arm (31% reduction). This remains one of the most replicated findings in metabolic medicine.
Sleep
Sleep optimization is the least prescribed and most underestimated lifestyle intervention for insulin resistance. The mechanisms are now well established:
- Sleep deprivation elevates cortisol the following morning, which raises fasting glucose.
- Poor sleep reduces growth hormone secretion, which impairs overnight glucose regulation.
- Even modest sleep restriction reduces insulin sensitivity significantly — the equivalent effect of gaining several kilograms of body fat, in metabolic terms.
Canadian adults average 6.9 hours of sleep per night, short of the 7–9 hours the Public Health Agency of Canada recommends for adults. Closing that gap is part of a complete insulin-resistance treatment plan.
See if Cloudcure is right for you
Stress management
Chronic psychological stress is a direct driver of cortisol elevation, which is a direct driver of insulin resistance. Cognitive behavioural therapy (CBT), mindfulness-based stress reduction, and structured sleep-hygiene interventions all reduce cortisol and show secondary improvements in metabolic markers in clinical trials.
The practical implication for Canadians — who frequently cite stress as a top barrier to health behaviour change — is that addressing stress is not soft or peripheral to insulin resistance treatment. It is part of the mechanism.
When clinical support becomes appropriate
For many people, lifestyle intervention alone — sustained diet change, regular exercise, improved sleep — produces clinically meaningful improvements in insulin sensitivity and prevents progression to prediabetes or type 2 diabetes. The Diabetes Prevention Program's 58% risk reduction was achieved entirely through lifestyle change.
However, clinical support becomes appropriate when:
- Lifestyle change alone has been tried consistently for three to six months without sufficient metabolic response.
- The degree of insulin resistance is severe enough (very elevated HbA1c, significant beta-cell strain on bloodwork) that waiting on lifestyle-only response creates clinical risk.
- Comorbid conditions — PCOS, non-alcoholic fatty liver disease, sleep apnea — are compounding the metabolic burden and need coordinated management.
In those situations, Canadian-licensed physicians have several prescription options available when clinically appropriate. The longest-established first-line option is an insulin-sensitizing medication, which has the strongest long-term evidence base and the best safety record for prediabetes and insulin resistance. Newer prescription medications that work through gut-hormone pathways address insulin resistance through several mechanisms at once — supporting beta-cell function, influencing appetite signalling, and assisting weight reduction — and are increasingly considered in insulin-resistance management. A further class of prescription options can add cardiorenal benefits in specific clinical profiles. Which, if any, is appropriate is a decision a licensed clinician makes for the individual.
All of these require prescription by a licensed Canadian physician following a complete clinical assessment. They are adjunctive to lifestyle change, not substitutes for it.
The long-term stakes
Insulin resistance, left unaddressed, is the common root of most of the leading metabolic diseases in Canada:
- Type 2 diabetes — affects 3.3 million Canadians, per Diabetes Canada, and a significant proportion had addressable insulin resistance for years beforehand.
- Cardiovascular disease — hyperinsulinemia and the associated dyslipidemia (high triglycerides, low HDL) are established cardiovascular risk factors.
- Non-alcoholic fatty liver disease (MASLD) — insulin resistance drives hepatic fat accumulation, and the liver is often the earliest organ visibly affected on imaging. Our guide to fatty liver and weight loss covers what reverses it.
- PCOS — insulin stimulates ovarian androgen production, making insulin resistance the central metabolic driver of PCOS in most women, per the 2023 International PCOS Guideline. See our overview of what PCOS is in Canada.
- Hypertension — insulin promotes sodium retention; chronic hyperinsulinemia raises blood pressure through a well-characterized mechanism.
Addressing insulin resistance early — before glucose crosses the diagnostic threshold — is one of the highest-leverage interventions available in preventive medicine. The evidence is consistent, the interventions are proven, and the window is widest before the cascade is fully established.
Getting help
If you suspect insulin resistance based on bloodwork, family history, or the symptom picture described above, the starting point is your Canadian family physician. Ask for a full metabolic panel — fasting glucose, HbA1c, fasting insulin, lipid panel, and waist circumference. Most provincial plans cover this testing without a referral.
If your family physician has identified insulin resistance or prediabetes and you want structured, clinician-supervised support for the lifestyle intervention — the kind with monthly follow-up, lab monitoring, and a plan built around your specific metabolic markers — that's what Cloudcure is designed to provide.
We do not replace your family physician. We run the 12-month metabolic arc most family physicians don't have bandwidth to run — monthly check-ins, lab reviews at months 3, 6, and 12, nutrition and movement coaching built around your numbers, and coordinated communication with your existing care team.
Related reading. Because insulin resistance sits at the centre of so many conditions, a few companion guides go deeper on specific angles: our PCOS resource hub collects the women's-health picture, where insulin resistance is a core driver; our guide to sleep, cortisol and weight explains how poor sleep worsens insulin sensitivity; and our 72-hour fast safety guide covers extended fasting cautiously, including why anyone with established insulin resistance should approach it only with clinical oversight.
Start your eligibility check